Skip to main content

Table 1 Body weights and plasma glucose, triglyceride (TG), and non-esterified free fatty acid (NEFA) levels of four groups of mice before and after gavage

From: Small-molecule agonist AdipoRon alleviates diabetic retinopathy through the AdipoR1/AMPK/EGR4 pathway

Characteristic

HFD

DM

DMSO

AdipoRon

Fasting body weights

 Before

35.07 ± 3.95

25.94 ± 2.02

24.75 ± 1.91

25.48 ± 2.19

 After

38.15 ± 6.04

26.19 ± 1.97

25.31 ± 1.03

24.41 ± 1.89

 P-value

 < 0.05

/

/

/

Fasting plasma glucose

 Before

8.37 ± 1.45

24.85 ± 2.62

22.38 ± 4.63

23.69 ± 3.31

 After

8.81 ± 1.86

24.78 ± 2.78

23.43 ± 3.24

24.27 ± 2.33

 P-value

/

/

/

/

Fasting plasma TG

 Before

0.80 ± 0.23

1.16 ± 0.26

1.03 ± 0.38

1.07 ± 0.34

 After

1.03 ± 0.30

1.12 ± 0.38

1.08 ± 0.28

0.95 ± 0.28

 P-value

 < 0.05

/

/

/

Fasting plasma NEFA

 Before

0.46 ± 0.14

0.90 ± 0.26

0.76 ± 0.23

0.88 ± 0.24

 After

0.62 ± 0.19

1.00 ± 0.30

0.90 ± 0.43

0.92 ± 0.27

 P-value

 < 0.05

/

/

/

  1. HFD high-fat diet, DM high-fat diet + diabetes mellitus control, DMSO high-fat diet + diabetes mellitus + dimethyl sulfoxide negative control, AdipoRon, high-fat diet + diabetes mellitus + AdipoRon. The results are represented as mean ± standard deviation